FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1566007037> ?p ?o ?g. }

• W1566007037 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CAMetformin is an oral biguanide used for type II diabetes. Epidemiologic studies suggest a link between metformin use and reduced risk of breast and other types of cancers. erbB-2 expressing breast cancer is a subgroup of tumors with poor prognosis. Previous studies demonstrated that metformin is a potent inhibitor of erbB-2 overexpressing breast cancer cells; metformin treatment extends the life span and impedes mammary tumor development in ErbB-2 transgenic mice in vivo. However, the mechanisms of metformin associated anti-tumor activity, especially in prevention models, remain unclear. In this study, we investigated the mechanisms of metformin associated prevention/inhibition of ErbB-2 mediated breast cancer development by focusing on the potential effect of metformin on tumor initiating cells (TICs)/cancer stem cells (CSCs) in the MMTV-erbB-2 transgenic mouse model and its context with existing in vitro models. We report here for the first time that systemic administration of metformin (250 mg/kg/day, ip, between 8- and 18-week of age) selectively inhibits CD61high/CD49fhigh subpopulation, a group of TICs of MMTV-ErbB-2 mammary tumors, in preneoplastic mammary glands. Metformin also inhibited CD61high/CD49fhigh subpopulation in MMTV-erbB-2 tumor-derived cells, which was correlated with their compromised tumor initiation/development in a syngeneic tumor graft model. Molecular analysis indicated that metformin induced downregulation of erbB-2 and EGFR expression and inhibited the phosphorylation of erbB family members, IGF1R, Akt, mTOR and Stat3 in vivo. In vitro data indicate that low doses (1 mM) of metformin inhibited the self-renewal/proliferation of CSCs/TICs in ErbB-2-overexpressing breast cancer cells. We further demonstrated that the expression and activation of ErbB-2 were preferentially increased in CSC/TIC-enriched tumorsphere cells, which promoted their self-renewal/proliferation and rendered them more sensitive to metformin. Our results, especially the in vivo data, provide fundamental support for developing metformin-mediated preventive strategies targeting erbB-2-associated carcinogenesis.Citation Format: Pei Zhu, Meghan Davis, Amanda Blackwelder, Nora Bachman, Bolin Liu, Susan Edgerton, Leonard L. Williams, Ann D. Thor, Xiaohe Yang. Metformin selectively targets tumor initiating cells in erbb-2 overexpressing breast cancer models. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2967. doi:10.1158/1538-7445.AM2014-2967" @default.
• W1566007037 created "2016-06-24" @default.
• W1566007037 creator A5013400628 @default.
• W1566007037 creator A5019925910 @default.
• W1566007037 creator A5026320613 @default.
• W1566007037 creator A5026941470 @default.
• W1566007037 creator A5027579154 @default.
• W1566007037 creator A5038531636 @default.
• W1566007037 creator A5040402922 @default.
• W1566007037 creator A5048727442 @default.
• W1566007037 creator A5075327350 @default.
• W1566007037 date "2014-09-30" @default.
• W1566007037 modified "2023-09-26" @default.
• W1566007037 title "Abstract 2967: Metformin selectively targets tumor initiating cells in erbb-2 overexpressing breast cancer models" @default.
• W1566007037 doi "https://doi.org/10.1158/1538-7445.am2014-2967" @default.
• W1566007037 hasPublicationYear "2014" @default.
• W1566007037 type Work @default.
• W1566007037 sameAs 1566007037 @default.
• W1566007037 citedByCount "1" @default.
• W1566007037 countsByYear W15660070372014 @default.
• W1566007037 crossrefType "proceedings-article" @default.
• W1566007037 hasAuthorship W1566007037A5013400628 @default.
• W1566007037 hasAuthorship W1566007037A5019925910 @default.
• W1566007037 hasAuthorship W1566007037A5026320613 @default.
• W1566007037 hasAuthorship W1566007037A5026941470 @default.
• W1566007037 hasAuthorship W1566007037A5027579154 @default.
• W1566007037 hasAuthorship W1566007037A5038531636 @default.
• W1566007037 hasAuthorship W1566007037A5040402922 @default.
• W1566007037 hasAuthorship W1566007037A5048727442 @default.
• W1566007037 hasAuthorship W1566007037A5075327350 @default.
• W1566007037 hasConcept C121608353 @default.
• W1566007037 hasConcept C126322002 @default.
• W1566007037 hasConcept C150903083 @default.
• W1566007037 hasConcept C151730666 @default.
• W1566007037 hasConcept C190283241 @default.
• W1566007037 hasConcept C207001950 @default.
• W1566007037 hasConcept C2776187077 @default.
• W1566007037 hasConcept C2777688063 @default.
• W1566007037 hasConcept C2779251935 @default.
• W1566007037 hasConcept C2779306644 @default.
• W1566007037 hasConcept C2779343474 @default.
• W1566007037 hasConcept C2780323712 @default.
• W1566007037 hasConcept C502942594 @default.
• W1566007037 hasConcept C530470458 @default.
• W1566007037 hasConcept C55493867 @default.
• W1566007037 hasConcept C71924100 @default.
• W1566007037 hasConcept C86554907 @default.
• W1566007037 hasConcept C86803240 @default.
• W1566007037 hasConceptScore W1566007037C121608353 @default.
• W1566007037 hasConceptScore W1566007037C126322002 @default.
• W1566007037 hasConceptScore W1566007037C150903083 @default.
• W1566007037 hasConceptScore W1566007037C151730666 @default.
• W1566007037 hasConceptScore W1566007037C190283241 @default.
• W1566007037 hasConceptScore W1566007037C207001950 @default.
• W1566007037 hasConceptScore W1566007037C2776187077 @default.
• W1566007037 hasConceptScore W1566007037C2777688063 @default.
• W1566007037 hasConceptScore W1566007037C2779251935 @default.
• W1566007037 hasConceptScore W1566007037C2779306644 @default.
• W1566007037 hasConceptScore W1566007037C2779343474 @default.
• W1566007037 hasConceptScore W1566007037C2780323712 @default.
• W1566007037 hasConceptScore W1566007037C502942594 @default.
• W1566007037 hasConceptScore W1566007037C530470458 @default.
• W1566007037 hasConceptScore W1566007037C55493867 @default.
• W1566007037 hasConceptScore W1566007037C71924100 @default.
• W1566007037 hasConceptScore W1566007037C86554907 @default.
• W1566007037 hasConceptScore W1566007037C86803240 @default.
• W1566007037 hasLocation W15660070371 @default.
• W1566007037 hasOpenAccess W1566007037 @default.
• W1566007037 hasPrimaryLocation W15660070371 @default.
• W1566007037 hasRelatedWork W1565578858 @default.
• W1566007037 hasRelatedWork W1681190610 @default.
• W1566007037 hasRelatedWork W1972969589 @default.
• W1566007037 hasRelatedWork W1977846610 @default.
• W1566007037 hasRelatedWork W2028426028 @default.
• W1566007037 hasRelatedWork W2069220547 @default.
• W1566007037 hasRelatedWork W2071015820 @default.
• W1566007037 hasRelatedWork W2083620422 @default.
• W1566007037 hasRelatedWork W2094241128 @default.
• W1566007037 hasRelatedWork W2103576580 @default.
• W1566007037 hasRelatedWork W2136798608 @default.
• W1566007037 hasRelatedWork W2258459776 @default.
• W1566007037 hasRelatedWork W2316509354 @default.
• W1566007037 hasRelatedWork W2318960175 @default.
• W1566007037 hasRelatedWork W2320340098 @default.
• W1566007037 hasRelatedWork W2329016057 @default.
• W1566007037 hasRelatedWork W2483319710 @default.
• W1566007037 hasRelatedWork W2562564824 @default.
• W1566007037 hasRelatedWork W2886419069 @default.
• W1566007037 hasRelatedWork W2955178987 @default.
• W1566007037 isParatext "false" @default.
• W1566007037 isRetracted "false" @default.
• W1566007037 magId "1566007037" @default.
• W1566007037 workType "article" @default.